| Literature DB >> 32178315 |
Xiangyang Li1,2, Manli Guo2, Jingtian Chi2, Jiangang Ma1.
Abstract
Walnut residue is a kind of high-quality plant protein resource. The bioactive peptide prepared from walnut residue has excellent health care functions such as antioxidation and antihypertensive activity, but at present, walnut residue is often regarded as waste or low value feed, fertilizer and other materials. The uneconomical use of walnut residue has hindered the development of the walnut industry to some extent. Effective utilization of walnut residue protein to develop bioactive peptides and other products is of great significance to realize the comprehensive utilization of walnut residue, improve the added value of by-products, and change the current low utilization rate of walnut residue. In this paper, the preparation, purification and structure identification of walnut protein bioactive peptides are reviewed, and different functional walnut active peptides (WBPs) are introduced. The potential effects of these bioactivities on human health and their different uses in food, medicine and other industries are discussed. The purpose is to provide reference information for the effective utilization of walnut residue resources and the development of walnut industry.Entities:
Keywords: antihypertensive activity; antioxidation; bioactive peptide; preparation; walnut residue
Mesh:
Substances:
Year: 2020 PMID: 32178315 PMCID: PMC7143977 DOI: 10.3390/molecules25061285
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Amino acid composition (g/100 g) of degreased walnut powder and walnut protein [13,15,16].
| Amino Acids | DFWF | WPC | WPI | WHO/FAO/UNU (2007) * | |||
|---|---|---|---|---|---|---|---|
| 1–2 | 3–10 | 11–14 | Adults | ||||
| Met | 1.16 | 0.99 | 1.44 | 1.6 | |||
| Val | 4.18 | 3.50 | 4.62 | 4.2 | 4.0 | 4.0 | 3.9 |
| Thr | 3.58 | 2.55 | 3.30 | 2.7 | 2.5 | 2.5 | 2.3 |
| His | 2.38 | 1.89 | 2.30 | 1.8 | 1.6 | 1.6 | 1.5 |
| Ile | 3.28 | 3.03 | 3.99 | 3.1 | 3.1 | 30 | 3.0 |
| Leu | 7.13 | 5.64 | 7.29 | 6.3 | 6.1 | 6.0 | 5.9 |
| Lys | 2.58 | 2.01 | 2.13 | 5.2 | 4.8 | 4.8 | 4.5 |
| Cys | 0.84 | 0.70 | 0.81 | 0.6 | |||
| Phe | 4.94 | 3.49 | 4.61 | 3.8 ** | |||
| Tyr | 2.76 | 2.30 | 3.21 | 3.8 ** | |||
| Trp | 5.50 | 7.4 | 6.6 | 6.5 | 6.0 | ||
| Pro | 4.22 | 2.33 | 3.18 | ||||
| Ala | 4.74 | 3.31 | 4.29 | ||||
| Arg | 14.73 | 11.24 | 14.81 | ||||
| Gly | 5.43 | 3.54 | 4.18 | ||||
| Ser | 5.84 | 3.96 | 5.15 | ||||
| Glu | 22.16 | 15.78 | 19.49 | ||||
| Asp | 10.04 | 6.95 | 9.38 | ||||
DFWF, defatted walnut flour; WPC, walnut protein concentrate, WPI, walnut protein isolate; Met, methionine; Val, valine; Thr, threonine; His, histidine; Phe, phenylalanine; Ile, isoleucine; Leu, leucine; Lys, lysine; Pro, proline; Cys, cysteine; Tyr, tyrosine; Trp, tryptophan; Ala, alanine; Arg, argnine; Gly, glycine; Ser, serine; Glu, glutamic acid; Asp, aspartic acid; * Values in these columnsrepresentthe WHO/FAO/UNU (2007) recommended patterns of essential amino acids for 1–2, 3–10, 11–14 year oldchildren and adults. ** The total amount of Phe and Tyr is 3.8g/100g. a,b,c Numerical values with different letters in the same row are significantly different(P-value < 0.05).
Figure 1Technological process of preparing WBP by solid fermentation.
Some walnut antioxidant peptides that have been identified.
| Hydrolase | SIT | ACS * | RMM orM/C | Ref |
|---|---|---|---|---|
| Pepsin | RP-HPLC-ESI-MS | ADAF | 423.23 Da | [ |
| Trypsin | UPLC-ESI-MS / MS | WSREEQEREE | 1377 Da | [ |
| Trypsin | UPLC-ESI-MS / MS | ADIYTEEAGR | 1124 Da | [ |
| Neutral protease | RP-HPLC,nanoLC-ESI–MS/MS,de novo sequencing | LAGNPDDEFRPQ | 1357.6262 Da | [ |
| Neutral Protease | RP-HPLC,nanoLC-ESI–MS/MS, de novo sequencing | VEDELVAVV | 971.5080 Da | [ |
| Papain | RP-HPLC | CTLEW | 651.2795 Da | [ |
| Tripsin, Viscozyme L | UPLC-ESI-Q-TOF-MS/MS | GGW | 319.1400 Da | [ |
| Tripsin, Viscozyme L | UPLC-ESI-Q-TOF-MS/MS | VYY | 444.2129 Da | [ |
| Tripsin, Viscozyme L | UPLC-ESI-Q-TOF-MS/MS | LLPF | 489.3071Da | [ |
| Pancreatin | ESI-MS/MS | YS | 269.11 | [ |
| Pancreatin | ESI-MS/MS | YSVH | 505.23 | [ |
| Pancreatin | ESI-MS/MS | YK | 310.14 | [ |
| Pancreatin | ESI-MS/MS | YT | 283.13 | [ |
| Pancreatin | ESI-MS/MS | LPC | 331.16 | [ |
| Pancreatin | ESI-MS/MS | EM | 279.13 | [ |
| Pancreatin | ESI-MS/MS | CA | 192.14 | [ |
| Pancreatin | ESI-MS/MS | SQK | 362.3272 | [ |
| Pancreatin | ESI-MS/MS | CR | 288.2900 | [ |
| Pancreatin | ESI-MS/MS | CHC | 362.3265 | [ |
| Pancreatin | ESI-MS/MS | GHC | 316.3200 | [ |
| Pancreatin | ESI-MS/MS | YA | 253.1181 | [ |
| Pancreatin | ESI-MS/MS | YG | 239.1025 | [ |
| Pancreatin | ESI-MS/MS | NW | 318.3007 | [ |
| Alcalase and protamex | HPLC-FTMS, de novo sequencing, scoring method | VEGNLQVLRPR | [ | |
| Alcalase and protamex | HPLC-FTMS, de novo sequencing, scoring method | LAGNPHQQQQ | [ | |
| Alcalase and protamex | HPLC-FTMS, de novo sequencing, scoring method | HNLDTQTESDV | [ | |
| Alcalase and protamex | HPLC-FTMS, de novo sequencing, scoring method | AGNDGFEYVTLK | [ | |
| Alcalase | HPLC-FTMS, de novo sequencing, scoring method | WSVWEQELEDR | [ | |
| Alcalase and protamex | HPLC-FTMS, de novo sequencing, scoring method | QQRQQQGL | [ | |
| Alcalase and protamex | HPLC-FTMS, de novo sequencing, scoring method | AELQVVDHLGQTV | [ | |
| Alcalase and protamex | HPLC-FTMS, de novo sequencing, scoring method | EQEEEESTGRMK | [ | |
| Alcalase and protamex | HPLC-FTMS, de novo sequencing, scoring method | VEDELVAVV | [ | |
| Alcalase | LC-ESI-QTOF | AGGA | [ | |
| Simulating gastrointestinal digestion | RP-HPLC-UPLC-QTOF-MS | TY | [ | |
| Simulating gastrointestinal digestion | RP-HPLC-UPLC-QTOF-MS | SGGY | [ |
The SIT, ACS, RMM, M/C andRefin the table refer to separation and identification technology, amino acid sequence, relative molecular mass, mass/charge ratio and reference respectively. * The amino acid sequence is in the form of 20 single letter abbreviations, namely G—Gly, A—Ala, V —Val, L—Leu, I—Ile, P—Pro, S—Ser, T—Thr, H—His, E—Glu, D—Asp, Q—Gln, N—Asn, K— Lys, R—Arg, C—Cys, M—Met, F—Phe, Y—Tyr and W—Trp.
ACE inhibitor peptides that have been identified.
| Pre-Met | SIT | ACS * | RMM | IC50 | Ref |
|---|---|---|---|---|---|
| Enzymolysis | UF, GPC-HPLC, MALDI-TOF-MS | TWPERPPQIP | 1033.42Da | 25.67 μg/mL | [ |
| Enzymolysis | UF, GPC, HPLC (RP-HPLC), ESI | YEP | 407.43Da | 0.29 μmol/L | [ |
| Enzymolysis | MALDI-TOF-MS, GPC-HPLC | LPGRPPIKPWPL | 1353.67 Da | 128.98 μg/mL | [ |
| Enzymolysis | RP-HPLC, HPLC | YVPHWDL | 929Da | 0.136–0.173 μm/mL | [ |
| Fermentation | UF, UPLC-ESI-MS/MS, RP-HPLC | VQTL | 459.35Da | - | [ |
| Enzymolysis | UPLC-Q-TOF-MS/MS, HPLC-MS/MS | EPNGLLLPQY | 1142.60 Da | 0.233 μm/mL | [ |
| Enzymolysis | UPLC-MALDI-TOF-MS | LY | 295.19Da | 0.042 μm/mL | [ |
| Enzymolysis | UPLC-MALDI-TOF-MS | YLA | 366.24Da | 0.396 μm/mL | [ |
The Pre-met, SIT, ACS, RMM and Ref in the table refer to preparation method, separation and identification technology, amino acid sequence, relative molecular mass and reference, respectively. * The amino acid sequence is in the form of 20 single letter abbreviations, namely Gly—G, Ala—A, Val—V, Leu—L, Ile—I, Pro—P, Ser—S, Thr—T, His—H, Glu—E, Asp—D, Gln—Q, Asn—N, Lys—K, Arg—R, Cys—C, Met—M, Phe—F, Tyr—Y and Trp—W.